HomeNewsBusinessStocksStocks in news: Sun Pharma, Tata Steel, KEC, HPCL, Hindalco

Stocks in news: Sun Pharma, Tata Steel, KEC, HPCL, Hindalco

Sun Pharma | Tata Steel | Larsen and Toubro | Crompton Greaves | Ballarpur Industries | TRF | KEC International | HPCL | JK Lakshmi Cement | Prestige Estates | Aksh Optifibre | NMDC | Godawari Power | Hindalco Industries and Reliance Power are stocks, which are in the news today.

August 12, 2015 / 11:01 IST
Story continues below Advertisement

Here are stocks that are in news today:Results today: Coal India, JSPL, Ashok Leyland, Aurobindo Pharma, Cadila Healthcare, Oil India, India cement, Reliance Infra, Voltas, Aditya Birla Nuvo, Max India, IDBI Bank, Bank of Maharashtra, City Union Bank, Dhanlaxmi Bank, Natco Pharma, NALCO, Man Infra, Merck, MOIL, Simplex Infrastructure, Speciality Restaurants, Subex, Indian Hotels Company, Time Technoplast, Timken India, Titagarh Wagons, TVS Srichakra, Wheels India, Wonderla Holidays, Alembic, Anant Raj, AXISCADES Engineering, Ballarpur Industries, Balmer Lawrie, Balrampur Chini, Bartronics India, Career Point, Cigniti Tech, Daawat (LT Foods), Dhanuka Agritech, Dolphin Offshore, Emco, Emkay Global, FACT, Genus Power, Global Vectra Helicorp, Gokaldas Exports, Golden Tobacco, Himadri Chemicals, Honda Siel Power, Hotel Leela Venture, Jayaswal Neco, JBM Auto, Jubilant Industries, Kakatiya Cement, Kopran, Lovable Lingerie, Mukand Limited, NFL, Piramal Phytocare, Plastiblends India, Repro India, Rico Auto, Sanghvi Forging, Sanghvi Movers, Seamec, SCI, Shrenuj & Company, Talbros Automotive, GE Shipping, Unity Infra, Welspun Enterprises, Zicom Electronic, Zodiac Clothing, Zuari Agro

Sun Pharma Q1-Consolidated net profit down 46 percent at Rs 479 crore versus Rs 886.8 crore (QoQ)-Consolidated total income up 9.8 percent at Rs 6,757.6 crore versus Rs 6,157 crore (QoQ)-Consolidated EBITDA at Rs 1,859.7 crore versus Rs 792.3 crore (QoQ)-Consolidated EBITDA margin at 27.5 percent versus 13 percent (QoQ)-Consolidated exceptional loss at Rs 685 crore-Consolidated tax expense at Rs 226.8 crore versus tax credit of Rs 600 crore (QoQ)-All adjustments related to merger in Q1 earnings-Other income at Rs 105.4 crore versus Rs 382.5 crore (QoQ)-Recommends dividend of Rs 3/share

Story continues below Advertisement

Sun Pharma says-One-time loss of Rs 685 crore represents impairment charges on merger-Q1 US finished dosage sales down 4 percent at USD 488 million (YoY)-Q1 emerging markets sales down 15 percent at USD 133 million (YoY)-Q1 Rest Of World sales down 7 percent at USD 91 million (YoY)-Q1 R&D investments up 37 percent at Rs 511 crore (YoY)-Q1 earnings impacted by certain one-time & exceptional charges

Sun Pharma MD Dilip Shanghvi says-Continue to invest significantly in R&D & building critical talent-Have strengthened ophthalmology & OTC teams in US-Specific integration milestones include ensuring GMP compliance-Targetting more product filings globally-Q1 numbers not in line with company’s historical performance-Integrating a large business & have focussed on improving compliance-One-time charges will drive synergies & profitability in long-term-Some charges may continue in the near future-US sales impacted due to competitive pressure on some products-Regaining trust of customers & channels in US is foremost focus-Have a strong pipeline of 159 ANDA awaiting approvals in US-Competitive pressure on products like Doxycycline, Lipodox-Supply from Halol has improved, expect trend to continue going forward-Philosophy is to grow faster than market-Had guided flat to potential revenue reduction versus market growth-Plan to use this time to consolidate the base, get strong infra in place-Consumer health is a very important component-Takes time for market to regain momentum for a brand like Revital-Provisions of write-down to relate to plans of rationalising manufacturing footprint-Current provisions will reflect if we pursue plan of plant rationalisation-Focus is to get Xelpros into market at the earliest-Traditionally Sun portfolio growing faster than market in India-Comfortable with other segment growth too-Consumer health business important for future growth globally-Will try to achieve guided synergy as soon as possible-Grown faster than industry in chronic therapy market-Should see data for MK-3222 by end of 2015-Emerging market business impacted due to currencies fluctuations